GlaxoSmithKline, Vir look to succeed where Lilly failed with NIH antibody study in hospitalized Covid-19 patients

In the hunt for an effective Covid-19 therapy, monoclonal antibodies have turned up mixed data so far. Eli Lilly was Exhibit A in October when the NIH quickly cut its antibody from a trial in moderately ill hospitalized patients. But now, GlaxoSmithKline and partner Vir Biotechnology are hoping to succeed where Lilly failed.